Finance-Funding
-
Gearing Up For A Biotech M&A Boom
10/1/2021
Biotech M&A was slow in the first half of 2021, but that may be changing, with emerging trends indicating that a biotech M&A boom could be on the horizon. If your biotech is hoping to be acquired by a larger pharma company, it’s crucial that you start preparing now.
-
VCs Breathe New Life Into Life Sciences Industrials
9/1/2021
The “industrials” or supplier sector of the biopharma industry, in a significant change from the past, is now receiving an extra financial boost from VC funding. Why should their biopharma customers care?
-
IPO, M&A, And SPAC — 3 Life Science Execs Recount Going Public
8/2/2021
Taking a company public may not be every entrepreneur’s dream, but it is for many life sciences companies. As 2020 forever changed how IPOs are done, it seems like there is a great opportunity to capture some wisdom from those who have been there, done that.
-
How To Identify Capital To Fund Life Sciences Growth
6/1/2021
For life sciences companies, funding needs evolve at every stage of growth — creating both challenges and opportunities. Regardless of the stage, it is fundamental to align your funding strategy with your company’s vision.
-
Emerging Trends For Life Sciences IPOs During The Pandemic
1/4/2021
It is possible to take your company public without ever having to leave your home, but there are some key issues to consider when doing so.
-
Dealmakers In Life Sciences: More Active, More Creative
5/1/2020
“Our belief is that the underlying strength of the life sciences sector will continue to promote dealmaking activity going forward, continuing its outperformance of other sectors.”
-
The Evolving Payer Focus On Prevalence In Rare Diseases
4/1/2020
A recent analysis of trends in payer decisions related to reimbursement indicates that payers are looking at a range of issues, including disease prevalence, with new levels of scrutiny and are working to rein in pricing of many rare disease treatments.
-
How To Overcome The Challenge Of Valuing A Biotech
12/30/2019
Because of the unknowns around revenue streams, biotech valuation may appear to be more guesswork than science. However, common valuation methods can help account for some of the product-line uncertainty.
-
From Medtech CEO To Impact Investor — Not Your Typical Retirement Plan
11/1/2019
Tim Ring, former chairman and CEO of C.R. Bard, shares how he and his spouse retired to build TEAMFund, a $30 million impact investment fund focused on having a positive impact on health in some of the most resource constrained areas of the world.
-
7 Elements Of A Successful Biotech Funding Plan
11/1/2019
Life sciences companies seeking to raise capital or form early partnerships with strategic players often make avoidable mistakes. Here are some tips that can increase your probability of a successful transaction.